Precision Genomics Collaboratory News

Dr. Priya Kishnani grew up in a family of physicians, including her mother, a pediatrician, in Mumbai (then Bombay), India. “My mother ran a charitable program, caring for the underserved and indigent throughout her life,” Dr. Kishnani says. “I saw firsthand what it really meant to be a physician: to give hope to your neighbors, and make an impact on the rest of their lives. From then on, I knew this was what I wanted to do.”

Three Duke University School of Medicine researchers were named Burroughs Wellcome Fund 2021 Investigators in the highly competitive Pathogenesis of Infectious Disease (PATH) program.

A new $8 million NIH grant seeks to uncover more clues into what genes increase the risk of developing schizophrenia.

The Sequencing and Genomic Technologies (SGT) Core Facility has a new instrument on its bench

Snellings, a graduate student in Doug Marchuk's lab, is co-lead author on a new publication that uses single nucleus sequencing to better understand what causes some cerebral cavernous malformations to stay small and others to grow.

Two Duke faculty members have been elected as members of the U.S. National Academy of Sciences (NAS), one of the highest honors in the profession.

The American Association for Cancer Research (AACR) has named Jen-Tsan Ashley Chi, MD, PhD, as co-winner of the Molecular Cancer Research Michael B. Kastan Award for Research Excellence on behalf of his all-Duke research team for their paper — A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer.  

Some guys have it all: the muscle, the power, the high social status, the accelerated aging.

Breast cancer is the second most common cancer among women in the United States. One in eight women will develop the disease. Typically, patients respond well to initial treatment, which usually includes some combination of surgery, radiation, chemotherapy and hormone treatment.

Clinicians have historically used family health history collection as a primary method for identifying actionable disease-risk assessments. However, as large-scale genome screening programs continue to rise in popularity, the scientific community has questioned the efficacy of this traditional method, wondering at the superiority of variants identified by sequencing over family health history in identifying these risks.